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ABSTRACT: Introduction: There is currently an increasing use of biological agents in the management of Crohn’s disease (CD). 
There is lack of data regarding the epidemiological profile of patients on infliximab (IFX) and adalimumab (ADA) for CD in Brazil. 
Objective: To identify the epidemiological characteristics of patients with CD who underwent biological therapy. Method: Retro-
spective multicenter study, with CD patients on biological therapy. Analyzed variables: gender, age at treatment initiation, Montreal 
classification, concomitant perianal disease and smoking status. Results: 175 patients without previous exposure to biological agents 
were included, 93 (53%) were male. The mean age at treatment initiation was 35.5 (2-79) years old an the mean disease duration was 
46.9 (0-480) months. Overall, 117 (66.9%) patients used IFX and 58 (33.1%), ADA. Montreal classification: age at diagnosis ― A1 
(n=21; 12%), A2 (n=102; 58.3%), and A3 (n=52; 29.7%). CD location ― L1 (n=42; 24%), L2 (n=51; 29.1%), L3 (n=81; 46.3%), and 
L4 (n=1, 0.6%). Phenotype ―B1 (n=59; 33.7%), B2 (n=46; 26.3%), and B3 (n=70; 40%). Perianal disease was found in 89 (50.9%) 
patients. Conclusions: The epidemiological profile of patients was similar to the literature. There was a high prevalence of patients 
with fistulizing CD.
Keywords: Crohn’s disease; tumor necrosis factor-alpha; epidemiology.
RESUMO: Introdução: Atualmente há uso crescente dos agentes biológicos no manejo da doença de Crohn (DC). Há escassez de dados 
referentes ao perfil epidemiológico dos usuários de infliximabe (IFX) e adalimumabe (ADA) para DC no Brasil. Objetivo: Identificar as 
características epidemiológicas dos pacientes com DC submetidos à terapia biológica. Método: Estudo retrospectivo, multicêntrico, com 
portadores de DC que utilizaram terapia biológica. Variáveis analisadas: gênero, idade ao início do tratamento, classificação de Montreal, 
doença perianal concomitante e tabagismo. Resultados: Foram incluídos 175 pacientes, sem exposição prévia a biológicos, sendo 93 
(53%) homens. A média de idade no início do tratamento biológico foi de 35,5 (2-79) anos. O tempo médio de doença ao início do trata-
mento foi de 46,9 (0-480) meses. Do total da amostra, 117 (66,9%) utilizaram IFX e 58 (33,1%) ADA. Classificação de Montreal: idade 
ao diagnóstico ― A1 (n=21; 12%), A2 (n=102; 58,3%) e A3 (n=52; 29,7%). Localização da DC ― L1 (n=42; 24%), L2 (n=51; 29,1%), 
L3 (n=81; 46,3%) e L4 (n=1; 0,6%). Forma de apresentação ― B1 (n=59; 33,7%), B2 (n=46; 26,3%) e B3 (n=70; 40%). Doença perianal 
foi encontrada em 89 (50,9%) dos pacientes. Conclusões: Os dados epidemiológicos dos pacientes foram compatíveis com os da literatura 
internacional. Houve uma alta prevalência de pacientes com a forma fistulizante da DC.
Palavras-chave: Doença de Crohn; fator de necrose tumoral alfa; epidemiologia.
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INTRODUCTION
Crohn’s Disease (CD) is a chronic transmural 
inflammatory disease that may affect the whole gas-
trointestinal tract, and is characterized by alternate 
episodes of remission and reactivation. Its evolution 
throughout the years, due to its natural history, can 
cause complications such as stenosis, fistulas or ab-
scesses1. Nowadays, there is a global tendency that the 
CD incidence will increase, and this is confirmed by 
important retrospective epidemiological studies from 
the 1980’s2-4.
The pathogenesis of CD is not well understood, 
so there is no defined etiology for the disease5. Some 
believe in the existence of complex genetic and envi-
ronmental interactions that eventually predispose and 
trigger its pathological manifestations6. Its clinical pre-
sentation varies according to location, extension and in-
tensity of the inflammation of compromised sites5.
CD occurs mainly among adolescents and young 
adults, and represents an important social, psychologi-
cal and labor impact since it affects this age group of 
great productivity7. Because of this recurring pattern 
of symptoms and the evolution to the already men-
tioned complications, which lead more than 70% of 
patients to surgery and 30% to repeated resections, 
CD causes a significant impact on the physical and 
psychological quality of life of patients7,8.
The proper treatment for CD is yet significantly 
limited, since there is no type of clinical or surgical in-
tervention that can cure the disease5. Therefore, there 
is a constant search for new forms of treatment. In the 
past few years, the management of CD has evolved, 
especially due to the increasing use of biological 
agents all over the world1.
Until the end of the 1990s, when the first bio-
logical drug was approved for CD, the conventional 
therapeutic arsenal was composed of corticosteroids, 
antibiotics, aminosalicylates and immunomodulators 
(azathioprine, 6-mercaptopurine and methotrexate)5,8.
Nowadays, the objectives of CD treatment include 
the fast induction to clinical remission, with the effi-
cient maintenance of remission without the use of corti-
costeroids, as well as mucosal healing, closure of fistu-
las, prevention and reduction of the number of hospital 
admissions and surgeries, besides the improvement in 
the quality of life of patients. As an additional objective, 
the ability to prevent long term complications has been 
more and more discussed5. The drugs that are most 
likely to meet these objectives are the anti-TNF anti-
bodies, infliximab (IFX), adalimumab (ADA) and cer-
tolizumab pegol (CER), which are the only biological 
agents available in Brazil to handle the disease. Today, 
a great proportion of the patients with CD in outpatient 
clinics, doctors offices or reference centers, use these 
drugs. Due to the recent approval of CER in Brazil to 
manage CD, the number of patients being treated with 
this third agent is still small, but it should increase in 
the next years.
Currently, the incidence of CD in the United 
States is approximately 15 to 20 cases per 10 thou-
sand inhabitants2. It is difficult to measure this number 
in countries of Africa or Latin America, like Brazil, 
since the epidemiological data of the disease are only 
available in few publications. Therefore, there is no 
national prevalence or incidence rate that is officially 
acknowledged.
Even with data from isolated regions, it is pos-
sible to observe the increasing number of CD cases 
diagnosed in the past few decades in South America 
and Brazil2. Studies performed in the 1980s and 1990s 
in some states of Brazil showed dozens of new diag-
nosed cases, with much higher numbers in compari-
son to previous decades2.
In the international literature, many papers analyze 
isolated factors such as ethnicity, age, gender, medica-
tion, association with smoking and other variables. How-
ever, none of them have designed an epidemiological 
profile, including only patients with CD on anti-TNF 
therapy. In Brazil, both epidemiological data of patients 
with CD and on biological therapy are lacking.
With this scenario of limited data, this study 
aimed to identify the epidemiological characteristics 
of Brazilian patients with CD submitted to biologi-
cal therapy, based on baseline characteristics and the 
Montreal classification. Morover, it aims to determine 
which is the most frequent phenotype of the disease in 
this sample of patients and to compare this informa-
tion with data from the international literature.
METHOD
This study was carried out after the approv-
al by the Research Ethics Committee of Pontifícia 
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cal data to the analyzed ones were selected for fur-
ther comparison.
With complete protocols and literature review, 
data were compiled and organized in frequency tables. 
The obtained results from this sample were expressed 
by means, medians, minimum values, maximum val-
ues and standard deviation (quantitative variables) or 
by frequencies and percentages (qualitative variables). 
Each variable was individually analyzed with the ob-
jective to compare them with data found in literature.
RESULTS
The study included 175 patients, 93 (53%) were 
male and 82 (47%) female. In relation to age at the be-
ginning of biological treatment, a mean of 35.5 years 
old (2–79; SD=13.9) was found. The mean time of 
duration of CD at the beginning of treatment was 
46.9 months (0–480; SD=69.6). However, it was ob-
served that most cases (55.4%) started biological treat-
ment less than 24 months after the onset of the disease.
One hundred and forty-six patients (83.4%) were 
on concomitant use of azathioprine (AZA), using the 
strategy of combo therapy, more recently described1. 
Corticosteroids were used at the beginning of biologi-
cal treatment in 102 patients (58.3%). No patient used 
methotrexate. There were only 11 smoking patients, 
which corresponded to 6.3% of the total sample. Peri-
anal disease was found in 89 patients (50.9%). The 
biological therapies used were IFX in 117 (66.9%) 
patients and ADA in 58 (33.1%). No patient was on 
CER. Table 2 summarizes the baseline characteristics 
of the analyzed patients.
Universidade Católica do Paraná (PUC-PR), pro-
tocol number 0005580/11.
This was a retrospective, transversal multicenter 
study with patients with CD who were on biological ther-
apy from May 2000 to May 2012, coming from five dif-
ferent reference centers of inflammatory bowel disease 
(IBD) from the South and Southeast of Brazil.
The study included: patients with CD, users of 
IFX, ADA or CER as the first anti-TNF agent, who 
had not previously been on biological therapy, at any 
age. The study excluded: patients with ulcerative coli-
tis or indeterminate IBD, and those who were using a 
second biological drug in the treatment (patients with 
previous exposure to a first biological agent).
The study sample was not calculated, but per-
formed by means of a convenience sample, including 
the actual number of patients coming from the men-
tioned reference centers. A data review was conduct-
ed with information from medical files and posterior 
completion of a specific protocol, with previously 
chosen variables to be analyzed. When necessary, the 
patient received a phone call in case there was con-
flicted or missing information, to clear any doubts or 
to request any additional information. After the revi-
sion of medical files and data collection, 175 patients 
met the criteria and were included in this study.
All reference centers of IBD that offered their pa-
tients data manage CD according to the guidelines by 
the European Crohn’s and Colitis Organization (ECCO), 
which standardizes specially the indication to biological 
treatment in the included subjects9.
The analyzed variables were gender, age at biologi-
cal therapy initiation, time of diagnosis, associated perianal 
disease, concomitant medications, smoking, type of anti-
TNF agent anti-TNF (IFX, ADA or CER) and Montreal 
classification (age at diagnosis of CD, location of disease 
and phenotype). The Montreal classification is detailed in 
Table 1. Protocols were fulfilled based on the compiled 
data concerning the beginning of biological treatment, and 
not the time of diagnosis of CD.
Literature review was based on searches in the fol-
lowing databases: PubMed, MEDLINE and SciELO. 
The searched terms were: “infliximab”, “adalimumab”, 
“certolizumab pegol”, “anti-TNF”, “biologics” and 
“epidemiology”, always combined with “Crohn’s dis-
ease”. All relevant articles published until July 2012 
were reviewed, and those with similar epidemiologi-
Table 1. Detailed Montreal Classification, adapted 
from Silverberg et al.0.
Montreal Classification
Age at 
diagnosis (A)
A1 ≤16 years old
A2 17–40 years old
A3 ≥40 years old
Disease 
location (L)
L1 Terminal ileum
L2 Colon
L3 Ileum-colon
L4 Upper gastrointestinal tract
Behavior (B)
B1 Nonstenotic /non-penetrating 
B2 Stenotic
B3 Penetrating
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According to the Montreal classifi cation, the fol-
lowing results were obtained for each of the variables: 
age at diagnosis A1 (n=21; 12%), A2 (n=102; 58.3%) 
and A3 (n=52, 29.7%). CD location: L1 (n=42; 24%), 
L2 (n=51, 29.1%), L3 (n=81, 46.3%), and L4 
(n=1, 0.6%). So, there was a higher prevalence of pa-
tients diagnosed with CD between 17 and 40 years old 
(A2), patients with ileocolic location (L3) and with 
fi stulizing disease (B3). Figure 1 illustrates these data.
DISCUSSION
The determination of epidemiological characteris-
tics in patients with CD is very diffi cult, in Brazil and in 
other developing countries, due to the defi cient registra-
tion systems. It is more diffi cult to characterize patients 
with CD on biological therapy, because even in devel-
oped countries these data are controversial, and ana-
lyzed in different manners by the studies that are avail-
able in literature2. Some assess only isolated users of 
biological therapy, most of the time analyzing its effi ca-
cy, safety or loss of response11-16,18. Therefore, this study 
aimed to assess data from subjects coming from fi ve 
reference centers of IBD from the South and Southeast 
of Brazil in order to present a general epidemiological 
profi le of these patients, which is more adequate to our 
reality, and compare them with other studies conducted 
in Brazil and in other parts of the world.
The fi ndings in this study demonstrated the 
greater prevalence of CD in young patients – A2 in 
the Montreal classifi cation, and mean age of 35.5 years 
old – in accordance with national and international lit-
erature2,11-18. This fact reveals the great importance of 
diagnosis and adequate management of these patients, 
since it’s a period of major activity and productivity 
of subjects. Since the disease is considerably debilitat-
ing, both physically and emotionally, and because the 
treatment is long, these years in the patient’s life end 
up being compromised11,13.
The higher prevalence of male (53 versus 47%) 
was a bit different than fi ndings from literature, 
which presents 45 to 61.8% of female patients and 
32.8 to 55% of male patients2,11-18. According to 
Cosnes et al.17, in countries with low incidence of 
CD, in Europe and North America, the prevalence 
of the disease has increased among men, being simi-
lar or even superior to women.
Figure 1. Mo ntreal Classifi cation of the 175 patients submitted to 
biological therapy.
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Table 2. Baseline characteristics of the 175 analyzed 
patients.
n (%)
Gender
Male 93 (53)
Female 82 (47)
Used biological drug
ADA 58 (33.1)
IFX 117 (66.9)
Time of diagnosis (months)
<24 97 (55.4)
24 to 60 36 (20.6)
>60 42 (24.0)
Mean±SD 46.9±69.6
Median (range) 12.0 (0.0~480.0)
Age at treatment initiation (years)
Mean±SD 35.5±13.9
Median (range) 34.0 (2.0~79.0)
Azathioprine
Yes 146 (83.4)
No 29 (16.6)
Corticosteroids
Yes 102 (58.3)
No 73 (41.7)
Smoking
Yes 11 (6.3)
No 164 (93.7)
Perianal CD
Yes 89 (50.9)
No 86 (49.1)
SD: Standard deviation; CD: Crohn’s Disease; ADA: adalimumab; 
IFX: infl iximab.
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The other two analyzed variables that presented 
different numbers than those found in literature were 
the presence of perianal disease and smoking. Since 
the study was performed in specialized IBD centers, 
especially coloproctology units, more than half of the 
patients (50.9%) had associated perianal disease. This 
percentage was significantly different when compared 
to other papers in literature, which showed 13.1–42% 
patients affected by perianal disease2,11-13,16,17. Howev-
er, it is important to notice the increase of severe and 
complicated forms of CD, such as perianal compro-
mise or other conditions2. The presence of fistulae is 
especially emphasized, since they have a significant 
impact on the quality of life of patients and make the 
treatment for CD even more challenging13,15.
Regarding smoking, the difference was even 
greater. In this study, only 6.3% of patients smoked, 
while in literature this habit was present in 19 to 47.8% 
of the cases2,12,13,15-17. Maybe this fact is justified by the 
greater announcement of the relation between smok-
ing and the worse evolution of the disease, especially 
in patients’ associations and reference services.
In relation to immunosuppressive drugs, distinct 
values were found in comparison to the literature when 
analyzing only the use of AZA: 83.4% in this study and 
percentages between 25 and 49.7% in the international 
literature. However, in relation to the use of concomitant 
drugs, such as methotrexate, 6-mercaptopurine and ami-
nosalicylates, which are common in Europe and in the 
United States, if added to the use of AZA, the per-
centage is close to 70%2,11-16. These values suggest 
that even with adverse effects and slow action onset, 
there are benefits to the combined treatment with anti-
TNF that overcome its disadvantages1,14. The results 
presented by Colombel et al.1, in the SONIC study, 
demonstrated that the combined therapy of IFX and 
AZA presented better clinical remission rates for CD 
as well as mucosal healing, in comparison to mono-
therapy with IFX or AZA.
By analyzing the use of corticosteroids at the begin-
ning of biological treatment, 58.3% of the patients in this 
study used them. In the national and international litera-
ture, these values ranged from 26 to 77% of the cases, 
which demonstrates one of the great indications to use 
biological drugs for the treatment of CD, the corticoste-
roid dependency2,11-18. Brazilian studies that also reported 
the analysis of this variable, demonstrated that 67 to 77% 
of the patients were on the medication. These data may 
seem to reflect the tendency of the great use of cortico-
steroids in Brazil in relation to the other countries2,19,20.
It is very difficult to define which biological 
agent is more used nowadays. The most relevant in-
ternational studies on the subject aim to assess the 
safety and efficacy of each isolated drug2,11-16. National 
studies and other case series do not present these data 
comparatively2,19,20. Even though, a significantly high-
er prevalence of IFX is still observed, maybe for its 
longer presence in the market or because of its avail-
ability in some centers. It could also be due to the ex-
perience of professionals who prescribe it and handle 
it. However, ADA is being more and more used, so 
this difference is being reduced as observed in publica-
tions throughout the years1,2,15. It is certain that within 
a few years there will be a greater number of patients 
on CER, which was recently approved in Brazil to 
treat CD patients. The results in this study demonstrated 
66.85% of patients on IFX and 43.15% on ADA, with 
a clear progression on the use of ADA each year during 
the analyzed period. No patient was on CER. The main 
epidemiological data found in this study in comparison 
to data from literature are described on Table 3.
Concerning the Montreal classification, many 
studies were analyzed; however, those that described 
the samples with this system were not only studies with 
patients on biological treatment, but with CD in gener-
al. Some analyses that assessed only patients on ADA 
or IFX did not use this classification, since their objec-
tives were not related to epidemiological variables. So, 
the values found in this study were comparable to those 
of Brazilian analyses reflecting a reality closer to ours, 
besides an international study that aimed to expose the 
evolution of the incidence and prevalence of IBD, CD 
and ulcerative colitis, separately, throughout the years, 
which consistently demonstrated the prevalence of each 
one of the classifications2,17,19-21.
Group A2 in the Montreal classification (age 
at diagnosis between 17 and 40 years) was the most 
prevalent in this study, accounting for 58.3% of the 
patients. This number was similar to that of papers 
in literature analyzed in this comparison (between 
59 and 73%), which shows the great prevalence of CD 
and the biological treatment in this age group17,19-21.
The disease location was also shown in this study, 
and the percentages were in accordance with literature. 
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The most prevalent type was L3 (ileocolic CD), in 46.3% 
of the cases. In the literature, this was also the most com-
mon form observed in most of the reviewed studies, with 
percentages ranging from 34.5 and 47%2,17,19-21.
Regarding the behavior of CD, differences be-
tween the findings in this sample were found in com-
parison to literature. The B3 type (penetrating CD) was 
described as being the most frequent one, representing 
40% of the cases. In most studies, the B1 type was more 
prevalent (luminal CD), ranging between 29.2 and 71%. 
This fact can be explained by the conduction of studies 
in colorectal surgery units, instead of gastroenterology 
clinics, where the reference and indications for patients 
with fistulizing perianal CD is more prevalent2,17,19,20. 
The comparative data in the present sample in relation 
to the Montreal classification and other studies in litera-
ture are detailed in Table 4.
CONCLUSIONS
Patients with CD on biological treatment, who 
had not been previously on anti-TNF therapy, had 
mean age of 35.5 years old, and most of them were 
male (53%). The subtype A2, from the Montreal clas-
sification, was the most found one (68.3%), and ileo-
colic segment (L3) as the most frequent compromised 
location in 46.3% of the cases. Most patients were on 
treatment with AZA or corticosteroids together with 
the biological treatment. These data characterize an 
epidemiological profile compatible with that found in 
international literature.
The presence of perianal disease was shown in 
50.9% of the cases, and the subtype B3 from the Mon-
treal classification was present in 40% of the cases, 
with higher prevalence comparing to the literature.
Table 3. Clinical and epidemiological basal characteristics of patients in comparison to papers from the national 
and international literature.
Author 
Gender (%)
Mean age
Perianal 
Disease 
(%)
Smoking 
(%)
Concomitant 
AZA
(%)
Concomitant 
corticosteroid
(%)Male Female
Panaccione et al.11 43.1 56.9 37 22.4 – 46.4 47.4
Colombel et al.12 38.2 61.8 37.1 15.2 35.5 32.2 44.0
Lichtiger et al.13 40.9 59.1 40.8 13.1 23.5 41.2 42.3
Hanauer et al.14 42.0 58.0 35 – – 25.0 51.0
Sands et al.15 55.0 45.0 37 – 45.0 30.0 26.0
Schnitzler et al.16 39.0 61.0 33.9 28.0 47.8 49.7 32.2
Cosnes et al.17 54.0 46.0 33 31.0 19.0 – –
Souza et al.2 44.0 56.0 32 42.0 – 48.8 77.0
Kotze et al.8 46.3 53.7 36.7 50.0 – – 55.5
This study 53.0 47.0 35.5 50.9 6.3 83.4 58.3
AZA: azathioprine.
Author
Montreal
A1 A2 A3 L1 L2 L3 L4 B1 B2 B3
Teixeira et al.21 10.0% 72.0% 18.0% 34.5% 31.0% 34.5% 0.0% - - -
Souza et al.20 - - - 22.0% 29.0% 47.0% 2.0% 58.0% 19.0% 23.0%
Poli et al.19 8.0% 73.0% 19.0% 34.0% 15.0% 45.0% 1.0% 38.0% 26.0% 36.0%
Souza et al.2 8.0% 59.0% 33.0% 46.0% 10.0% 43.0% 1.0% 71.0% 8.0% 21.0%
Cosnes et al.17 11.0% 72.0% 17.0% 25.3% 27.2% 34.6% 13.1% 29.2% 33.6% 37.2%
This study 12.0% 58.3% 29.7% 24.0% 29.1% 46.3% 0.6% 33.7% 26.3% 40.0%
Table 4: Montreal classification: data found in this study compared with data from national and international literature.
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